Investigational new drugs for the treatment of resistant pneumococcal infections
- 29 July 2005
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 14 (8) , 973-995
- https://doi.org/10.1517/13543784.14.8.973
Abstract
Antibiotic resistance in Streptococcus pneumoniae is not only increasing with penicillin but also with other antimicrobial classes including the macrolides, tetracyclines and sulfonamides. This trend with antibiotic resistance has highlighted the need for the further development of new anti-infectives for the treatment of pneumococcal infections, particularly against multi-drug resistant pneumococci. Several new drugs with anti-pneumococcal activity are at various stages of development and will be discussed in this review. Two new cephalosporins with activity against S. pneumoniae include ceftobiprole and RWJ-54428. Faropenem is in a new class of beta-lactam antibiotics called the penems. Structurally, the penems are a hybrid between the penicillins and cephalosporins. Sitafloxacin and garenoxacin are two new quinolones that are likely to have a role in treating pneumococcal infections. Oritavancin and dalbavancin are glycopeptides with activity against methicillin-resistant S. aureus and vancomycin-resistant Enterococcus spp. as well as multi-drug resistant pneumococci. Tigecycline is the first drug in a new class of anti-infectives called the glycycyclines that has activity against penicillin-resistant pneumococci.Keywords
This publication has 70 references indexed in Scilit:
- Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States over a 10-year period: Alexander ProjectDiagnostic Microbiology and Infectious Disease, 2005
- Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolatesDiagnostic Microbiology and Infectious Disease, 2004
- Fluoroquinolone and Other Antimicrobial Resistance in Invasive Pneumococci, Hong Kong, 1995–2001Emerging Infectious Diseases, 2004
- Multiple-Dose Pharmacokinetics and Safety of a Novel Broad-Spectrum Cephalosporin (BAL5788) in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2004
- Single-Dose Pharmacokinetics and Safety of a Novel Broad-Spectrum Cephalosporin (BAL5788) in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2004
- Use of Monte Carlo Simulations To Select Therapeutic Doses and Provisional Breakpoints of BAL9141Antimicrobial Agents and Chemotherapy, 2004
- Diagnosis and Management of Acute Otitis MediaPediatrics, 2004
- Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent AdultsClinical Infectious Diseases, 2003
- In Vitro and In Vivo Properties of Ro 63-9141, a Novel Broad-Spectrum Cephalosporin with Activity against Methicillin-Resistant StaphylococciAntimicrobial Agents and Chemotherapy, 2001
- Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United StatesAntimicrobial Agents and Chemotherapy, 1990